title: A case of encapsulating peritoneal sclerosis at the clinical early stage with high concentration of matrix metalloproteinase-2 in peritoneal effluent.
abstract: In encapsulating peritoneal sclerosis (EPS), matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases are involved in the remodeling of peritoneal tissue. We measured the MMP-2 concentration in the peritoneal effluents of a patient with EPS who discontinued continuous ambulatory peritoneal dialysis (CAPD) therapy because of ultrafiltration failure and/or underdialysis. First, we report a 58-year-old female patient who discontinued CAPD therapy because of underdialysis. Several months after cessation of CAPD, she complained of slightly blood-colored ascites and had an elevated level of C-reactive protein (CRP) in plasma. She was diagnosed as having clinical early-stage EPS. Peritoneal effluents drained from this case, and from 11 patients who discontinued CAPD therapy because of ultrafiltration failure and/or underdialysis, and who underwent peritoneal lavage with 1.5% dextrose peritoneal dialysis fluid for several months, were analyzed by gelatin zymography. MMP-2 concentration was also measured by enzyme-linked immunosorbent assay (ELISA). MMP-2 concentration in peritoneal effluent of this patient was highest compared with that of the other patients. There was some tendency of a positive correlation between MMP-2 concentration per 1 g protein and D/Pcr, and was negative correlation between MMP-2 concentration per 1 g of protein and D/D0 glucose. We concluded that MMP-2 is involved in the peritoneal remodeling of long-term CAPD therapy and the progression of EPS.
authors.affiliation: Division of Nephrology, Department of Internal Medicine, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi-machi, Kawachi-gun, Tochigi 329-0498, Japan. masunaga-npr@umin.ac.jp
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Masunaga
authors.forename: Ichiro
authors.initials: I
authors.lastname: Hirahara
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Shimano
authors.forename: Megumi
authors.initials: M
authors.lastname: Kurosu
authors.forename: Osamu
authors.initials: O
authors.lastname: Iimura
authors.forename: Yukio
authors.initials: Y
authors.lastname: Miyata
authors.forename: Morimasa
authors.initials: M
authors.lastname: Amemiya
authors.forename: Sumiko
authors.initials: S
authors.lastname: Homma
authors.forename: Eiji
authors.initials: E
authors.lastname: Kusano
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Asano
mesh_terms: D001202:Ascitic Fluid / Q000201:enzymology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D008875:Middle Aged; D009994:Osmolar Concentration; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010532:Peritoneal Diseases / Q000175:diagnosis / Q000201:enzymology* / Q000209:etiology* / Q000473:pathology; D011860:Radiography, Abdominal; D012598:Sclerosis; D014057:Tomography, X-Ray Computed; D014463:Ultrasonography
chemical_list: D020778:Matrix Metalloproteinase 2